Tag Archives: VOICE trial

IAS 2019: While plans for HIV control innovations accelerate, community input remains an afterthought

By on .

MEXICO CITY – “What HIV has pointed out is that building it does not make them come,” Ambassador Dr. Deborah Birx noted at an opening night press event that highlighted persisting gaps in HIV testing, treatment, prevention access across the globe. When services don’t reach clients and communities, she said, people offering them have to […]

Microbicides and other ARV-based prevention: Biomedical answers meet challenges on the ground

By on .

Does adherence to using a product intended to prevent HIV acquisition depend on willingness, or ability to use the product? What are the factors — whether thoughts, beliefs, structural obstacles or social barriers — influencing both? The challenges that women have faced since the recognition of HIV in protecting themselves from getting the virus by […]

International Partnership for Microbicides, pharmaceutical company agreement sets path for woman-controlled HIV prevention

By on .

The announcement today that Janssen R&D Ireland pharmaceutical company will give the nonprofit International Partnership for Microbicides exclusive worldwide rights to develop, make and market sexual and reproductive health products with the antiretroviral dapivirine was heralded by both organizations as a stride for global public health in general, and HIV prevention for women in particular. The […]

The Year in Global Health: Top 10 stories in HIV, TB around the world

By on .

HIV, TB research, funding, policy developments, setbacks of 2013 lay out promises and challenges for 2014 The PEPFAR Stewardship and Oversight Act – In a year when Congress couldn’t even keep the Panda-cam on, expectations for the future of the legislation that launched PEPFAR and that was set to expire this year were low. The […]

After VOICE trial, question remains: What were women telling researchers?

By on .

Science Speaks is in Atlanta, Georgia this week and will be live-blogging from the 20th CROI — Conference on Retroviruses and Opportunistic Infections from Sunday to Wednesday, covering breaking developments from investigators on cure research, new antiretroviral agents, hepatitis, tuberculosis and treatment as prevention. Perhaps at some point what the VOICE trial (Vaginal and Oral […]